Search Results

Aravive, Inc., announced that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended and suspend its public reporting obligations.

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported first quarter 2023 financial results and provided corporate updates.

Aravive, Inc. (Nasdaq: ARAV, “the Company”) today announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in the pre-specified subset of patients naïve to prior bevacizumab treatment.

Aravive, Inc. announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.

Aravive, Inc. today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain.

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually.

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that in accordance with Nasdaq rules regarding employment inducement awards, the Company has granted an equity compensation award to a new employee.

Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC).

Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced it will host a virtual Key Opinion Leader event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET.

Aravive, Inc. today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates.